![]() What questions do you have? This is what it does. We’re going to see our patients with heart failure and COPD and start talking to them: “There’s an RSV vaccine out. Welch, PharmD, MBA, FAPhA: What practitioners can do now is plant the seed. ![]() Let’s try to avoid another crisis like last year, when we saw all those unnecessary deaths.Īdam C. We need to emphasize that, from a payer standpoint, the data are there. Usually, they meet again in August, and all those recommendations are finalized. Although they may not be published until January or February, because that’s when they come out every year, those recommendations are finalized by the end of that last meeting. If you’re like me-a vaccine nerd who watches the ACIP meetings live-you can see them. It’s just a matter of getting all those aligned so we can have vaccines ready to go and be paid for, and the pharmacist ready to inject them come this RSV season.Ĭhristina Madison, PharmD, FCCP, AAHIVP: I want to reiterate that those meetings are all public. Payers have the tools they need to make the decisions to cover these vaccines. The meetings of discussion from the FDA and the CDC are out there. They have the tools they need to make that decision because the phase 3 trials for these vaccines have been published in the New England Journal of Medicine. We might miss that window unless payers react before the MMWR publication comes out. But in a couple of months, we’ll be knee-deep in RSV season and influenza season. It could take several months for the CDC to take the ACIP recommendations, formulate the publication, and get it out there. Payers will include coverage for vaccines once the ACIP recommendations are published in the Morbidity Mortality Weekly Report. It’s going to require a lot of entities to come on board and recognize the importance of RSV prevention through vaccines. Will we be ready to target those vulnerable adults, age 60 and older, come this RSV season? We’re not sure. RSV season seems to resemble flu season, which is in October. The FDA approved the first RSV vaccine in older adults in May. Welch, PharmD, MBA, FAPhA: This is an interesting, timed vaccine as far as the approval. Dr Welch, when we think about RSV, what are the potential obstacles that we have related to administration, such as antigenic groups or even payer coverage?Īdam C. ![]() Ryan Haumschild, PharmD, MS, MBA: Everyone knows that as we’re developing different vaccination strategies, we have to be proactive in addressing barriers because they exist across all patient types and a lot of diseases. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |